The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ASMB | +65.63% | -84.59% | -31.19% | -93% |
| S&P | +16.23% | +94.45% | +14.22% | +442% |
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
The clinical-stage biotech had a big pipeline setback.
An enthusiastic price for a secondary share offering lifted spirits and the stock.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $9.63M | 12.8% |
| Gross Profit | $9.59M | 12.9% |
| Gross Margin | 99.67% | 0.0% |
| Market Cap | $138.39M | 63.6% |
| Market Cap / Employee | $1.90M | 0.0% |
| Employees | 73 | 12.3% |
| Net Income | -$10.20M | 8.6% |
| EBITDA | -$11.06M | 9.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $24.01M | 25.0% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.35M | 421.3% |
| Short Term Debt | $0.53M | -58.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -39.74% | 10.4% |
| Return On Invested Capital | -93.93% | -15.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$16.76M | 2.1% |
| Operating Free Cash Flow | -$16.76M | 2.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.77 | 3.86 | 2.14 | 5.09 | 120.51% |
| Price to Sales | 3.39 | 3.64 | 2.23 | 4.17 | 15.77% |
| Price to Tangible Book Value | 2.77 | 3.86 | 2.14 | 5.09 | 120.51% |
| Price to Free Cash Flow TTM | 2.40 | 2.65 | 3.21 | 4.21 | - |
| Enterprise Value to EBITDA | -0.24 | 0.45 | 1.64 | -6.02 | -343.94% |
| Free Cash Flow Yield | 41.7% | 37.8% | 31.1% | 23.7% | - |
| Return on Equity | -120.5% | -107.9% | -133.7% | -147.6% | 45.07% |
| Total Debt | $1.44M | $3.09M | $3.02M | $2.88M | 65.18% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
